BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 30886228)

  • 1. Sulfate depletion triggers overproduction of phospholipids and the release of outer membrane vesicles by Neisseria meningitidis.
    Gerritzen MJH; Martens DE; Uittenbogaard JP; Wijffels RH; Stork M
    Sci Rep; 2019 Mar; 9(1):4716. PubMed ID: 30886228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High dissolved oxygen tension triggers outer membrane vesicle formation by Neisseria meningitidis.
    Gerritzen MJH; Maas RHW; van den Ijssel J; van Keulen L; Martens DE; Wijffels RH; Stork M
    Microb Cell Fact; 2018 Oct; 17(1):157. PubMed ID: 30285743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cysteine depletion causes oxidative stress and triggers outer membrane vesicle release by Neisseria meningitidis; implications for vaccine development.
    van de Waterbeemd B; Zomer G; van den Ijssel J; van Keulen L; Eppink MH; van der Ley P; van der Pol LA
    PLoS One; 2013; 8(1):e54314. PubMed ID: 23372704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spontaneously released Neisseria meningitidis outer membrane vesicles as vaccine platform: production and purification.
    Gerritzen MJH; Salverda MLM; Martens DE; Wijffels RH; Stork M
    Vaccine; 2019 Nov; 37(47):6978-6986. PubMed ID: 31383485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic Similarity of Gonococcal Homologs to Meningococcal Outer Membrane Proteins of Serogroup B Vaccine.
    Marjuki H; Topaz N; Joseph SJ; Gernert KM; Kersh EN; ; Wang X
    mBio; 2019 Sep; 10(5):. PubMed ID: 31506309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outer membrane vesicles (OMVs) and detoxified lipooligosaccharide (dLOS) obtained from Brazilian prevalent N. meningitidis serogroup B strains protect mice against homologous and heterologous meningococcal infection and septic shock.
    Jessouroun E; da Silveira IF; Larangeira AP; Pereira S; Fernandes SA; Rabinovitch L; Frasch CE; Castro-Faria-Neto HC; Bozza PT
    Vaccine; 2004 Jun; 22(20):2617-25. PubMed ID: 15193387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous production of Neisseria meningitidis outer membrane vesicles.
    Gerritzen MJH; Stangowez L; van de Waterbeemd B; Martens DE; Wijffels RH; Stork M
    Appl Microbiol Biotechnol; 2019 Dec; 103(23-24):9401-9410. PubMed ID: 31676919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines.
    Sanders H; Feavers IM
    Expert Rev Vaccines; 2011 Mar; 10(3):323-34. PubMed ID: 21434800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of the biological activities of meningococcal endotoxins by association with outer membrane proteins is not inevitably linked to toxicity.
    Quakyi EK; Hochstein HD; Tsai CM
    Infect Immun; 1997 May; 65(5):1972-9. PubMed ID: 9125592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next-generation outer membrane vesicle vaccines against Neisseria meningitidis based on nontoxic LPS mutants.
    van der Ley P; van den Dobbelsteen G
    Hum Vaccin; 2011 Aug; 7(8):886-90. PubMed ID: 21785281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outer membrane vesicles as platform vaccine technology.
    van der Pol L; Stork M; van der Ley P
    Biotechnol J; 2015 Sep; 10(11):1689-706. PubMed ID: 26912077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed genome-derived neisserial antigen 1870.
    Hou VC; Koeberling O; Welsch JA; Granoff DM
    J Infect Dis; 2005 Aug; 192(4):580-90. PubMed ID: 16028126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of human CEACAM1 in transgenic mice limits the Opa-specific immune response against meningococcal outer membrane vesicles.
    Zariri A; van Dijken H; Hamstra HJ; van der Flier M; Vidarsson G; van Putten JP; Boog CJ; van den Dobbelsteen G; van der Ley P
    Vaccine; 2013 Nov; 31(47):5585-93. PubMed ID: 23933369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process.
    van de Waterbeemd B; Streefland M; van der Ley P; Zomer B; van Dijken H; Martens D; Wijffels R; van der Pol L
    Vaccine; 2010 Jul; 28(30):4810-6. PubMed ID: 20483197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical immunogenicity study of trivalent meningococcal AWX-OMV vaccines for the African meningitis belt.
    Tunheim G; Naess LM; Acevedo R; Fjeldheim ÅK; Bolstad K; García L; Cardoso D; Aase A; Zayas C; González H; Rosenqvist E; Norheim G
    Vaccine; 2014 Nov; 32(49):6631-8. PubMed ID: 25305564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meningococcal Outer Membrane Vesicle Composition-Dependent Activation of the Innate Immune Response.
    Zariri A; Beskers J; van de Waterbeemd B; Hamstra HJ; Bindels TH; van Riet E; van Putten JP; van der Ley P
    Infect Immun; 2016 Oct; 84(10):3024-33. PubMed ID: 27481244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the key antigenic components and pre-clinical immune responses to a meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles.
    Finney M; Vaughan T; Taylor S; Hudson MJ; Pratt C; Wheeler JX; Vipond C; Feavers I; Jones C; Findlow J; Borrow R; Gorringe A
    Hum Vaccin; 2008; 4(1):23-30. PubMed ID: 17921703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outer membrane vesicles extracted from Neisseria meningitidis serogroup X for prevention of meningococcal disease in Africa.
    Acevedo R; Zayas C; Norheim G; Fernández S; Cedré B; Aranguren Y; Cuello M; Rodriguez Y; González H; Mandiarote A; Pérez M; Hernández M; Hernández-Cedeño M; González D; Brorson SH; Rosenqvist E; Naess L; Tunheim G; Cardoso D; García L
    Pharmacol Res; 2017 Jul; 121():194-201. PubMed ID: 28495657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surface display of a borrelial lipoprotein on meningococcal outer membrane vesicles.
    Salverda ML; Meinderts SM; Hamstra HJ; Wagemakers A; Hovius JW; van der Ark A; Stork M; van der Ley P
    Vaccine; 2016 Feb; 34(8):1025-33. PubMed ID: 26801064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies for development of universal vaccines against meningococcal serogroup B disease: the most promising options and the challenges evaluating them.
    Holst J
    Hum Vaccin; 2007; 3(6):290-4. PubMed ID: 17712231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.